Ribo-regulators that sense trace antibiotics

Informacje na temat projektu

DrugSense

Identyfikator umowy o grant: 704340

DOI

10.3030/704340

Projekt został zamknięty

Data podpisania przez KE 21 Kwietnia 2016

Data rozpoczęcia 1 Maja 2016

Data zakończenia 30 Kwietnia 2017

Finansowanie w ramach

• EXCELLENT SCIENCE - European Research Council (ERC)

Koszt całkowity

€ 150 000,00

Wkład UE

€ 150 000,00

Koordynowany przez

WEIZMANN INSTITUTE OF SCIENCE
Israel

Periodic Reporting for period 1 - DrugSense (Ribo-regulators that sense trace antibiotics)

Okres sprawozdawczy: 2016-05-01 do 2017-04-30

Podsumowanie kontekstu i ogólnych celów projektu

The DrugSense project was aimed at commercializing the technology developed at the Sorek lab at the Weizmann Institute of Science, covered under U.S. provisional patent application 62/200,662. As planned, the expenses were used to cover the commercialization efforts as well as proof of concept experiments. These efforts resulted in the commercialization of the technology, which was eventually licensed by BiomX, a company developing novel therapeutics to alleviate microbiome-related diseases.


There is no overlap between the time that the PI dedicate to this project- DraugSense and the time that the PI dedicate to project PROKRNA.